SEMA4G: A Protein Involved in Cellular Processes and Potential Drug Target

Target Name: SEMA4G

NCBI ID: G57715

SEMA4G

SEMA4G: A Protein Involved in Cellular Processes and Potential Drug Target

SEMA4G, short for small heat-induced agglutination of erythrocytes, is a variant of the SEMAl cluster of genes that encode for the protein SMA (single-chain alpha-helical nucleosome)4G. SMA is a key protein that is involved in the regulation of microtubules, which are important for the proper functioning of cells.

SEMA4G is a 21-kDa protein that is expressed in a variety of tissues, including muscle, nerve, and heart cells. It is highly expressed in muscle cells, which require the services of SMA4G in order to maintain proper muscle function. SEMA4G is also expressed in other tissues, including the brain, where it is involved in the regulation of neuronal communication.

One of the key functions of SMA4G is its role in the regulation of microtubules. Microtubules are important for the proper functioning of cells, as they provide structural support for the cell and help to regulate the movement of cells and organelles. SMA4G is involved in the regulation of microtubule dynamics and stability, which is essential for the proper functioning of cells.

SEMA4G is also involved in the regulation of the cytoskeleton. The cytoskeleton is the structure that surrounds the cell and provides structural support. SMA4G is involved in the regulation of the cytoskeleton, which is essential for the proper functioning of cells.

SEMA4G is also involved in the regulation of cell adhesion. Cell adhesion is the process by which cells stick together and form tissues. SMA4G is involved in the regulation of cell adhesion, which is essential for the proper functioning of tissues.

SEMA4G is also involved in the regulation of inflammation. Inflammation is a critical response of the immune system to harmful stimuli, and SMA4G is involved in the regulation of inflammation.

SEMA4G is a potential drug target and may be a biomarker for a variety of diseases. For example, SEMA4G has been shown to be involved in the regulation of muscle strength and function, which is important for the treatment of muscle-related diseases, such as muscular dystrophy and myopathies.

SEMA4G may also be involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and can be treated with drugs that target SMA4G.

In addition to its potential therapeutic applications, SEMA4G is also a potential biomarker for a variety of diseases. For example, SEMA4G has been shown to be involved in the regulation of cancer cell growth and metastasis. This may make it an attractive target for cancer therapies.

Overall, SEMA4G is a versatile protein that is involved in a variety of important cellular processes. Its involvement in the regulation of microtubules, cytoskeleton, cell adhesion, and inflammation makes it a potential drug target and biomarker for a variety of diseases. Further research is needed to fully understand the functions of SEMA4G and its potential as a therapeutic agent.

Protein Name: Semaphorin 4G

Functions: Cell surface receptor for PLXNB2. May play a role in axon guidance (By similarity)

The "SEMA4G Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEMA4G comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets